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Objectives This study sought to evaluate the relationship between coronary endothelial function
and neointimal coverage after drug-eluting stent (DES) implantation.
Background The mechanisms of endothelial dysfunction after DES implantation remain to be fully
elucidated. We hypothesized that poor neointimal coverage after DES implantation may be associ-
ated with endothelial dysfunction distal to the stent site.
Methods Sixty-six stable angina patients treated with a ﬁrst-generation DES were enrolled. At
9-month follow-up, coronary endothelial function was evaluated with intracoronary infusion of incre-
mental doses of acetylcholine (108, 107, and 106 mol/l) and nitroglycerin (200 g). Vascular re-
ponses at the segments proximal and distal to the stent site were angiographically and quantita-
ively measured. At the same time, the degree of neointimal coverage was evaluated using coronary
ngioscopy and classiﬁed into 4 grades: 0 (no coverage) to 3 (full coverage).
esults We divided the subjects into poor-coverage (grades 0 to 1, n  33) and good-coverage
(grades 2 to 3, n  33) groups. Acetylcholine induced dose-dependent coronary vasoconstrictions in
both groups. At the segment distal to the stent, the magnitude of vasoconstriction to acetylcholine
in the poor-coverage group was signiﬁcantly greater than in the good-coverage group (p  0.001),
whereas vasomotor responses proximal to the stent and vasodilation by nitroglycerine were similar
between the 2 groups.
Conclusions Coronary endothelial dysfunction distal to the stent was associated with poor neointi-
mal coverage after DES implantation. (J Am Coll Cardiol Intv 2012;5:966–73) © 2012 by the
American College of Cardiology Foundation
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967The penetration of drug-eluting stents (DES), compared
with bare-metal stents (BMS), has significantly reduced
in-stent restenosis and target lesion revascularization after
percutaneous coronary intervention (1,2). Despite these
benefits, there is no evidence that DES improve mortality
rates when compared with BMS use (1,2). Furthermore, the
concerns of late stent thrombosis (LST) and very late stent
thrombosis (VLST) after DES implantation have arisen
(3,4). Although the incidences of LST and VLST are low,
they occur steadily at a constant rate of 0.4% to 0.6% per
year up to 3 years after first-generation DES implantation
(sirolimus-eluting stents [SES] and paclitaxel-eluting stents
[PES]) (5,6) and may be life threatening. The mechanisms
of LST and VLST have not been fully elucidated. Several
factors may be involved, such as patient-related issues,
lesion characteristics, and procedural-related variables, as
well as cessation of dual antiplatelet therapy (7). Previous
histopathological studies have suggested that poor re-
endothelialization may be associated with LST and VLST
after DES implantation (8,9). Recently, several clinical
studies have revealed coronary endothelial dysfunction at
segments adjacent to the first-generation DES implanted
site (10–12). Endothelial dysfunction is a well-known factor for
thrombosis. Thus, poor re-endothelialization at the stent site
and endothelial dysfunction adjacent to the stent site may
work together to produce LST and VLST. In this context,
we previously reported in the canine model of acute coro-
nary syndrome that endothelium function was impaired
distal to the thrombotic site of coronary arteries (13).
However, as far as we know, there have been no clinical
studies available in which poor re-endothelialization and
adjacent endothelial function were investigated simultane-
ously in humans in vivo.
To evaluate the magnitude of endothelialization in hu-
man coronary arteries has been challenging. Imaging mo-
dalities such as intravascular ultrasound or coronary angiog-
raphy are unsatisfactory. In this regard, coronary angioscopy
has been used to visually evaluate and inspect the macro-
scopic pathology at the stent site. Several coronary angio-
scopic observational data revealed poor neointimal coverage
and thrombus formation at the first-generation DES im-
planted site (14–16). However, endothelial function was
not examined in these studies and therefore the association
of neointimal coverage with endothelial function has been
unknown.
Accordingly, the objective of this study was to clarify the
relationship between neointimal coverage and coronary
endothelial function in patients treated with first-generation
DES.
Methods
Study protocol. From January 2009 to June 2010, 66 pa-
ients diagnosed as having stable angina and treated with aingle DES for a de novo lesion were enrolled in this study.
ES (Cypher, Cordis Corporation, Miami Lakes, Florida)
ere implanted in 40 patients, and PES (Taxus, Boston
cientific Corporation, Natick, Massachusetts) were im-
lanted in 26 patients. All stents were implanted using
tandard percutaneous coronary intervention techniques.
ollow-up coronary angiography, coronary endothelial
unction evaluation, and coronary angioscopy were per-
ormed 9 months after percutaneous coronary intervention.
he following subjects were excluded from this study: acute
nd old myocardial infarction; clinical or angiographic
istory of coronary vasospasm; previous coronary bypass
raft surgery; left main coronary artery lesion; bifurcation
esion requiring 2 stents; chronic total occlusions; in-stent
estenosis lesion; angiographic in-stent restenosis by
ollow-up angiography; symptomatic congestive heart fail-
re; severe left ventricular dysfunction (ejection fraction
30%); and severe valvular heart disease. This study was
pproved by the institutional re-
iew board of Kurume Univer-
ity, and all patients provided
ritten informed consent.
Medication regimen. All patients
received aspirin (100 mg/day) and
clopidogrel (75 mg/day) during the
follow-up period. Statin and renin-
angiotensin system inhibitor, in-
cluding angiotensin-converting en-
zyme inhibitor and angiotensin
receptor blocker were administered
daily to all patients. These drugs
may have salutary effects on coro-
nary endothelial function (17–19).
Evaluation of coronary endothelial
function. Coronary endothelial
unction was estimated by mea-
uring coronary vasomotion in response to acetylcholine
Ach) at 9-month follow-up. All vasoactive medications,
ncluding calcium channel blockers, long-acting nitrates,
ngiotensin-converting enzyme inhibitors, angiotensin recep-
or blockers, and beta-blockers, were discontinued at least
8 h before the test. After baseline angiography,
ndothelium-dependent vasomotor response was evaluated
y intracoronary infusion of incremental doses of Ach at
08, 107, and 106 mol/l for 2 min. At least 3 min was
allowed between each infusion. If clinically needed, a
temporary pacemaker was inserted through the femoral
vein. Subsequently, endothelium-independent vasomotor
response was tested after an intracoronary bolus infusion of
nitroglycerin (NTG) (200 g). Angiography was repeated
every 30 s for 2 min after each drug infusion. The maximal
vasomotor responses to Ach and NTG infusion were
Abbreviations
and Acronyms
Ach  acetylcholine
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
LST  late stent thrombosis
NTG  nitroglycerin
PES  paclitaxel-eluting
stent(s)
rs  Spearman rank
correlation coefficient
SES  sirolimus-eluting
stent(s)
VLST  very late stent
thrombosisdetermined by quantitative coronary angiography with a
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968CAAS II system (Pie Medical BV, Maastricht, the Neth-
erlands). Quantitative coronary angiography measurements
were performed by an independent blinded reviewer. Two
segments, 5 to 15 mm proximal and distal to the stent, were
analyzed. Additionally, as a reference, we evaluated an
angiographically normal segment in another vessel. If the
stent was in the right coronary artery, an angiographically
normal segment as far away as possible from the stent was
analyzed as the reference. The same segments were identi-
fied by anatomic landmarks and assessed at each measure-
ment. Changes in the vessel diameter in response to Ach
and NTG infusion were calculated as the percentage of
changes versus the baseline coronary diameter.
Angioscopic procedures and evaluation. Angioscopy was
performed after assessment of endothelial function. We
used a balloon occlusion type of coronary angioscopy
(VecmovaNEO, FiberTech, Tokyo, Japan). Details about
the procedure and specifications for these devices have been
described elsewhere (20). Briefly, the angioscopic fiber was
placed distal to the stent and was manually pulled back from
distal to proximal segment of the stent under careful
angioscopic and angiographic guidance. When the field of
view was flushed clear of blood with lactated Ringer’s
solution, inflation of the occlusion balloon was constantly
maintained. Each angioscopic image acquisition took from
15 to 25 s, and all sequences were recorded on digital video
disks for subsequent offline analysis. Angioscopic images
were evaluated with a focus on the following: 1) the dominant
degree of neointimal coverage over the stent; 2) existence of
Figure 1. Angioscopic Images of Neointimal Coverage Grade, Thrombus, an
Grade 0: fully visible stent struts are similar to appearance immediately after s
ing into the lumen and transparently visible. Grade 2: stent struts embedd
and not visible. Thrombus: red thrombus formation inside the stent site. H
ment. *The position of the guidewire.thrombus inside the stent; and 3) presence of heterogeneousneointimal coverage in the entire stent (Fig. 1). The degree
of neointimal coverage over the stent was classified into 4
grades as previously described (14–16): grade 0, fully visible
stent struts similar to immediately after stent implantation;
grade 1, stent struts with very thin neointimal coverage, but
protruded into the lumen and transparently visible; grade 2,
stent struts embedded by neointima, but seen translucently;
and grade 3, stent struts fully embedded and not visible by
angioscopy. If various grades were seen in the stent, we
judged this as heterogeneous coverage, and the dominant
pattern in the entire stent was used as the grade of the stent.
Thrombus inside the stent was defined on the basis of the
criteria adopted by the European Working Group on
Coronary Angioscopy (21). The angioscopic analysis was
performed offline by 2 independent observers (Observers 1 and
2), who were blinded to patient and stent information and to
the result of endothelial function evaluation. If there was a
disagreement between the 2 observers, a third observer was
recruited to resolve the conflict.
Statistical analysis. Statistical analysis was performed using
the SPSS (version 11.0, SPSS Inc., Chicago, Illinois). All
continuous data are given as mean  SD or median
(interquartile range), according to their normal or not
normal distribution. Before statistical analysis, normalcy
and homogeneity of the variances were tested using
Kolmogorov-Smirnov test and Levene test. Categorical
variables are presented as number or percentage. To analyze
the association between the neointimal coverage and the
erogeneous Coverage
mplantation. Grade 1: stent struts with very thin neointima, but protrud-
neointima but seen translucently. Grade 3: stent struts fully embedded
eneous coverage: various neointimal coverage grades within a stent seg-d Het
tent i
ed by
eterogvascular response to Ach, we performed Spearman rank
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969correlation test. Comparisons within groups on percentage
of changes in vessel diameter were performed by analysis of
variance for repeated measurements. For intergroup com-
parisons, unpaired t test or Mann-Whitney U test was
pplied in continuous variables, and chi-square test or
isher exact test was used in categorical variables. The group
nd location differences on percentage of changes in vessel
iameter were tested by 2-way analysis of variance for
epeated measurements. To identify factors that were
ndependently associated with endothelial dysfunction,
inear regression analyses were used. Including only
ariables with a p  0.05 on simple linear regression test,
orward stepwise multivariate regression analysis was
erformed. A 2-tailed p value 0.05 was considered
Table 1. Baseline Patient, Lesion, and Procedural Ch
Poor-Covera
(n 
Age, yrs 69.4
Men 25 (75
Body mass index, kg/m2 24.0
Systolic blood pressure, mm Hg 136.9
Diastolic blood pressure, mm Hg 68.2
Hypertension 22 (66
LDL cholesterol, mg/dl 121.6
HDL cholesterol, mg/dl 52.1
Dyslipidemia 16 (48
Hemoglobin A1c, % 6.2
Diabetes mellitus 18 (54
Smoking 15 (45
Family history of CAD 5 (15
CKD, eGFR 60 ml/min/1.73 m2 7 (21
Left ventricular ejection fraction, % 66.0
Medications
Statin 19 (57
Antidiabetic drug 13 (39
ACEI or ARB 20 (60
Calcium-channel blocker 18 (54
Beta-blocker 13 (39
Pre-diameter stenosis, % 76.0
AHA/ACC type B2 or C 20 (60
Stent deployment pressure, atm 12.8
Stent diameter, mm 3.1
Stent length, mm 25.8
Sirolimus-eluting stent 21 (63
Coronary artery lesion
Left anterior descending 8 (24
Left circumﬂex 20 (60
Right 5 (15
Values are mean SD or n (%).
ACCAmerican College of Cardiology; ACEI angiotensin-convert
receptor blocker; CAD coronary artery disease; CKD chronic kidn
lipoprotein; LDL low-density lipoprotein.statistically significant. tResults
The degree of vasoconstriction to 108, 107, and 106
mol/l Ach at the distal segment to the stent had a significant
correlation with the grade of neointimal coverage, respec-
tively (Ach 108, Spearman rank correlation coefficient [rs] 
0.24, p  0.04; Ach 107, rs  0.37, p  0.01; and Ach
06, rs 0.29, p 0.01), but not at the proximal segment
o the stent. For further evaluation, we divided our subjects
nto the 2 groups according to the grade of neointimal
overage as previously described (14). There were 33 pa-
ients in the good-coverage group (grades 2 to 3) and 33 in
he poor-coverage group (grades 0 to 1). The baseline
atient, lesion, and procedural characteristics were similar in
eristics
oup Good-Coverage Group
(n  33) p Values
69.0 9.6 0.86
22 (66.7) 0.59
24.0 3.5 0.95
133.0 7.8 0.10
66.9 13.1 0.64
26 (78.8) 0.41
111.2 33.5 0.19
47.0 11.3 0.06
17 (51.5) 1.00
6.0 0.8 0.48
14 (42.4) 0.46
11 (33.3) 0.45
2 (6.1) 0.43
7 (21.2) 1.00
65.2 8.2 0.68
18 (54.6) 1.00
13 (39.4) 1.00
17 (51.5) 0.62
13 (39.4) 0.32
12 (36.4) 1.00
79.6 10.2 0.24
19 (57.6) 1.00
12.6 3.7 0.86
3.0 0.4 0.87
23.7 6.0 0.18
19 (57.6) 0.80
5 (15.2) 0.38
17 (51.5) 0.47
11 (33.3) 0.15
yme inhibitor; AHAAmerican Heart Association; ARB angiotensin
se; eGFR estimated glomerular filtration rate; HDL high-densityaract
ge Gr
33)
8.4
.8)
4.3
10.8
9.0
.7)
31.0
10.6
.5)
0.8
.5)
.5)
.2)
.2)
6.9
.6)
.4)
.6)
.6)
.4)
14.0
.6)
3.1
0.3
6.5
.6)
.2)
.6)
.2)
ing enz
ey diseahe 2 groups (Table 1). Follow-up data are listed in Table 2.
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970Because the data of in-stent late loss did not show normality
and homogeneity of variance, we have reported medians
(interquartile rage) of in-stent late loss and performed
Mann-Whitney U test for comparison. There was a trend
oward greater in-stent late loss in the good-coverage
roup than in the poor-coverage group, but it was not
tatistically significant (p  0.07) (Table 3). In addition,
o adverse cardiac events occurred during the follow-up
eriod, and no patients showed in-stent restenosis on
ollow-up angiography.
Coronary endothelial function. In both groups, Ach induced
ose-dependent vasoconstrictions significantly at the seg-
ents both proximal (p 0.01) and distal (p 0.01) to the
tent. Vasoconstrictions to Ach were significantly greater at
he segment distal to the stent than at the one proximal to
he stent in both groups (p  0.01). At the segment
roximal to the stent, coronary vasomotor responses to Ach
ere similar between the 2 groups (p  0.50) (Fig. 2). In
Table 2. Patient Characteristics at Follow-Up
Poor-Coverag
(n  33
Systolic blood pressure, mm Hg 122.7 1
Diastolic blood pressure, mm Hg 67.4 7
LDL cholesterol, mg/dl 82.3 2
HDL cholesterol, mg/dl 53.8 1
Hemoglobin A1c, % 6.0 0
Medications
Statin 33 (100
Antidiabetic drug 13 (39.4
ACEI or ARB 33 (100
Calcium-channel blocker 17 (51.5
Beta-blocker 18 (54.6
Aspirin  clopidogrel 33 (100
Values are mean SD or n (%).
Abbreviations as in Table 1.
Table 3. Angiographic and Angioscopic Findings at F
Poor-Cov
(n
In-stent late loss, mm 0.10
Grade of neointimal coverage (SES/PES)
0 9
1 24
2
3
In-stent thrombus, % 20
SES/PES 9
Heterogeneous coverage, % 14
SES/PES 5
Values are median (interquartile range), n, or n (%).PES paclitaxel-eluting stent(s); SES sirolimus-eluting stent(s).ontrast, vasoconstrictions to Ach distal to the stent in the
oor-coverage group were significantly greater than in the
ood-coverage group (p  0.001) (Fig. 2). Endothelium-
ndependent vasodilation to NTG distal to the stent was
imilar between the 2 groups (Fig. 2). Comparing SES and
ES, coronary vasomotor responses to Ach and NTG were
imilar at the segments both proximal and distal to the stent
proximal: p  0.97; distal: p  0.47).
Angioscopic ﬁndings. The distribution of dominant neoin-
timal coverage grading is shown in Table 3. Thrombus and
heterogeneous coverage were more frequently observed in
the poor-coverage group than in the good-coverage group
(Table 3). Comparing SES and PES, PES showed a
higher incidence of thrombus and heterogeneous cover-
age than SES did (thrombus: 57.7% [15 of 26] vs. 22.5%
[9 of 40], p  0.01; heterogeneous coverage: 53.9% [14
of 26] vs. 12.5% [5 of 40], p  0.01, PES vs. SES,
respectively).
p Good-Coverage Group
(n  33) p Values
122.2 8.6 0.85
68.8 8.1 0.47
89.9 23.2 0.19
49.5 12.0 0.14
6.2 1.0 0.34
33 (100) 1.00
16 (48.5) 0.62
33 (100) 1.00
15 (45.5) 0.81
15 (45.5) 0.62
33 (100) 1.00
Up
Group Good-Coverage Group
(n  33) p Values
) 0.40 (0.03–0.60) 0.07
— —
) — —
17 (12/5) —
16 (7/9) —
4 (12.1) 0.001
0/4 —
5 (15.2) 0.03
0/5 —e Grou
)
1.3
.3
3.9
1.4
.5
)
)
)
)
)
)ollow-
erage
 33)
(0–0.38
(7/2)
(14/10
—
—
(60.6)
/11
(42.4)
/9
g
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971Independent factors of endothelial dysfunction distal to the
stent after ﬁrst-generation DES implantation. A linear re-
ression analysis was performed to determine the factors of
asomotor response to Ach (106 mol/l) distal to the stent.
Type of stent (SES or PES), existence of heterogeneous
neointimal coverage, and patient and lesion variables were
not associated with the vasomotion to Ach distal to the stent. The
presence of intrastent thrombus, poor coverage (grade 0 or
1) or good coverage (grade 2 or 3), and the grade of
neointimal coverage (grades 0 to 3) were significantly
associated with the magnitude of vasoconstriction to Ach
(106 mol/l) distal to the stent in a simple linear regression
(p  0.001, p  0.001, and p  0.01, respectively). In a
stepwise multivariate regression analysis, the presence of in-
trastent thrombus and the poor coverage or good coverage were
determined as the independent factors of endothelial dysfunc-
tion distal to the stent after first-generation DES implantation
(p  0.001 and p  0.04, respectively) (Table 4).
Discussion
The present study demonstrated that coronary vasoconstric-
tion in response to Ach at the segment distal to the stent site
was significantly greater in the group with poor neointimal
coverage estimated by coronary angioscopy than that in the
group with good neointimal coverage at 9-month follow-up
Figure 2. Changes in Vessel Diameter in Response to Ach and NTG Infusio
Expressed as percentage of changes versus the baseline diameter. The p value
group. Ach  acetylcholine; NTG  nitroglycerin.
Table 4. Independent Factors of Endothelial Dysfunc
DES Implantation
Simple Regression
r p Values
Presence of thrombus 0.42 0.001
Poor-coverage group/
good-coverage group†
0.41 0.001
*Vascular motion in response to acetylcholine (106 mol/l) at segmecoverage grade 2 or 3.after first-generation DES implantation. In this study,
in-stent thrombus formation and heterogeneous neointimal
coverage were more frequently observed in the poor-
coverage group than in the good-coverage group. Our
findings suggest that coronary endothelial function distal to
the stent could be deteriorated by the impaired arterial
healing at the stent after DES implantation.
Coronary endothelium-dependent vasomotor response after
DES implantation. In the present study, vasomotor response to
Ach distal to the stent was significantly different between the
poor-coverage group and the good-coverage group. The ques-
tions are raised whether this difference has been affected by the
systemic factors or the stent type. In these respects, first, the
difference in vasomotor responses was not due to the athero-
sclerotic risk factors, medications, lesion characteristics, and
procedural-related factors, because they were similar in the 2
groups at both baseline and follow-up. Second, this vasomotor
response distal to the DES site was not caused by systemic
vascular response, because vasoconstrictive responses to Ach
were similar between the 2 groups and vasodilation by NTG
were similar between the 2 groups at the reference segment.
Third, vasomotor responses to Ach or NTG were similar
between SES and PES. Therefore, vasoconstriction to Ach
distal to the stent could be related to a local-regional response
regardless of the stent type.
cate difference between the poor-coverage group and the good-coverage
istal to the Stent* After First-Generation
Stepwise Multivariate Regression
Beta Coefficient p Values Adjusted R2
0.42 0.001 0.23
0.27 0.04
l to drug-eluting stent (DES). †Poor coverage  grade 0 or 1; goodn
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972Under healthy endothelial conditions, Ach causes vaso-
dilation by inducing the release of nitric oxide. By contrast,
if endothelial dysfunction exists, paradoxical vasoconstric-
tive response to Ach is observed because of a disturbed nitric
oxide release and vasoconstriction of the vascular smooth
muscle (22). In the present study, the vasoconstriction to
Ach distal to the stent was more intense in the poor-
coverage group than in the good-coverage group, whereas
the vasodilator response to NTG was similar between the 2
groups, which indicated functional impairment of the en-
dothelium and preserved vascular smooth muscle dilator
function. In the previous studies, although coronary vaso-
constriction to Ach was observed in both SES and PES,
endothelium-dependent vasomotion in BMS was preserved
at 6 to 9 months after stenting (10–12). A possible explanation
for this difference may be that re-endothelialization is nearly
completed after BMS implantation (23), but not after
DES implantation (8,9). Accordingly, endothelium-
dependent vasoconstriction distal to the stent may be
associated with the incomplete re-endothelialization
and/or endothelial dysfunction at the stented site after
SES and PES implantation.
Arterial healing and re-endothelialization after DES implantation.
Delayed arterial healing is a well-known phenomenon after
SES and PES implantation in the previous pathological or
imaging-modality studies (8,9,14–16). In this study, coro-
nary angioscopy revealed the individual variation of arterial
healing within SES or PES. Most notably, the prevalence of
thrombus was more frequent in the poor-coverage group
than in the good-coverage group, because it has been
reported that not only the lack of neointimal coverage in
stent struts correlates with thrombus formation (24), but
also that the presence of uncovered struts without re-
endothelialization is the most powerful predictor of throm-
bus formation (9). Detection of poor neointimal coverage
and/or thrombus formation by coronary angioscopy in this
study could indicate the existence of impaired re-
endothelialization, although it may be difficult to confirm
the impaired re-endothelialization in clinical settings. Thus,
there could be differences in terms of in-stent re-
endothelialization between the poor-coverage group and the
good-coverage group.
Re-endothelialization at the stent site and endothelium-
dependent vasomotor response distal to the stent. The
nderlying mechanisms of impaired endothelium-
ependent vasomotor response distal to the DES site have
ot been well recognized. Our data demonstrate that the
everities of endothelium-dependent vasoconstriction distal
o the stent were associated with the impaired arterial
ealing, such as poor neointimal coverage and thrombus
ormation at the stent site, whereas endothelium-dependent
asomotion proximal to the stent was comparable in all
ubjects. Possible mechanisms for impaired endothelial
unction distal to the stent are considered as follows. First,he antiproliferative drugs may have locally diffused through
aso vasorum to the nonstented distal segments, leading to
mpaired endothelial function distal to the stent after DES
mplantation (25). Second, we have previously demon-
trated in the canine model of acute coronary syndromes
hat the adhesive interaction between activated platelets and
eukocytes plays an important role in endothelial injuries of
he coronary artery distal to the thrombotic site. Namely,
he lack of full endothelialization of the DES site would
redispose thrombus formation at the stent site. The
hrombi formed at the stent site release several vasoactive
ubstances that are shed into the distal site of the stent and
ould impair the distal endothelial function as we dem-
nstrated in the canine model (13,26). Although the
athophysiology at the DES site was different from that
t the artificially created stenosis in our previous canine
odel of acute coronary syndromes, the common patho-
hysiological findings between them may be localized
nflammatory reactions at the culprit site. Thus, several
ytotoxic substances released from the DES site might be
esponsible for impaired endothelial function distal to the
tent.
Study limitations. First, this study was a relatively small,
onrandomized single-center study. Second, our study
nded at 9 months after DES implantation, thus our
esults refer to this specific point. Moreover, it remains
nknown whether endothelial dysfunction associated
ith DES would persist beyond 9 months. Finally, the
linical outcome of our results in the long term remains
nknown. To overcome the previously mentioned limi-
ations, a prospective, randomized multicenter, long-
erm follow-up study will be required.
Clinical implication. It is important to detect coronary
endothelial dysfunction in patients with coronary artery
disease, because coronary endothelial dysfunction has
been indicated as an independent predictor of atheroscle-
rotic disease progression and cardiovascular event rates
(27). Furthermore, the previous histopathological study
documented that the occurrence and existence of uncov-
ered struts complicated by a dysfunctional endothelium
remain the primary cause of LST or VLST in DES (8,9).
The present study is a first report to reveal the relation-
ship between delayed arterial healing and coronary endo-
thelial function within the first-generation DES.
Conclusions
This study demonstrates that coronary endothelial dysfunc-
tion distal to the stent is associated with poor neointimal
coverage at the stent site at 9 months after first-generation
DES implantation.
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